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Introduction: Microtubule-actin crosslinking factor 1 (MACF1) is a key cytoskeletal
linker and plays a critical role in numerous cells [1]. We have previously demon-
strated MACF1 to be highly expressed in osteoblastic cells and participated in
the osteoblasts response to environmental stimuli [2]. However, the role of
MACF1 in osteoblast function is not well understood. Studies show that MACF1 is
critical for embryo development by activating Wnt/b-catenin signalling, which
also plays a key role in regulating osteoblast differentiation. We therefore aimed
to investigate whether MACF1 regulates osteoblast differentiation through Wnt/b-
catenin signalling in this study.
Subjects and Methods: Stable MACF1-knockdown MC3T3-E1 preosteoblasts con-
structed by lentivirus-mediated short-hairpin RNA (shRNA) targeting MACF1 gene
were adopted. The MC3T3-E1 preosteoblasts infected by control-shRNA were
used as a control. Alizarin red s staining was applied to detect mineralised nodules
formation. Real time PCR was used to detect the mRNA expression of alkaline
phosphatase (ALP), runt-related transcription factor 2 (Runx2), and T-cell factor
1 (TCF1). The luciferase reporter assay was further used to detect the TCF1 tran-
scriptional activity. Moreover, the b-catenin and GSK-3b levels were measured by
western blot with and without lithium chloride treatment.
Results: MACF1-knockdown (MACF1-KD) significantly inhibited mineralised nodules
formation and osteogenic gene expression. The translocation of b-catenin into the
nucleus was decreased by MACF1-knockdown and the downstream TCF1 transcrip-
tional activity and Runx2 expression were significantly suppressed. However, 6
hour treatment of 30mMLiCl inhibitedGSK-3b activation, induced b-catenin nuclear
translocation and partly restored the decreased expression of TCF1 and Runx2.
These findings showed that MACF1 deficiency inhibited osteoblast differentiation
and the nuclear translocation of b-catenin, suggesting that MACF1 positively regu-
lates osteoblast differentiation and may act through GSK3b/b-catenin signalling.
Discussion and Conclusion: The present study uncovers, for the first time an
important role of MACF1 in osteoblasts and suggests that MACF1 may positively
regulate osteoblast differentiation via b-catenin/TCF1-Runx2 signalling and acts
upstream of GSK-3b/b-catenin signalling.
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Background and objective: Osteosarcoma is the most common primary malig-
nancy of bone. Abnormal expression and activation of the receptor tyrosine ki-
nases (RTKs) play a vital role in the occurrence and development of
osteosarcoma. Studies show that c-Kit, a type III RTK, which is activated by itsligand, stem cell factor (SCF), and the newly-identified signalling mediator Gai
were both over-expressed in human OS tissues and cell line. The two also formed
a signalling complex. Further studies showed that c-Kit-Gai recruited the adaptor
protein Gab1 (Grb2-associated binder 1) to transduce downstream signalling. This
study was designed from a perspective of signalling pathway to investigate the role
of c-Kit-Gai complex in the proliferation of osteosarcoma.
Methods: The expression of Gai1/3, c-kit, and Gab1 of OS cell lines (U2OS, MG-63),
osteoblasts (MC3TC-E1), and bone cells (OB-6) were detected by western blot.
MG63 cells were incubated with 0, 0.1, 1, 5, 25, and 50ng/ml of SCF for 24 and
48 hours. The cell proliferation was detected by Brdu method and the cell survival
was detected by MTT. The MG63 cells were cultured with 50ng/ml SCF for 0, 5, 10,
20, and 30 minutes, western blot was used to detect the expression of T- Kit, P-Kit,
T-Gab1, P-Gab1, T-AKT, Akt473, P-S6K, P-PLC, T-PLC, T-S6, P-S6, T-ERK, and P-
ERK. We used the shRNA-mediated silencing or genetic knockout of Gai in the
MG-63 cells, and further detection of the activation conditions of Akt-mTOR and
Erk-MAPK downstream signalling (T-AKT, Akt473, Akt308, GSK3a/3b, mTOR, S6K,
S6, ERK) in the cells induced by SCF.
Results: The expression of c-Kit, Gai1/3, and Gab1 in cultured OS cell lines (U2OS,
MG-63) was significantly higher than those of osteoblasts (MC3TC-E1) and bone
cells (OB-6). In MG-63 cells, the exogenous SCF increased the phosphorylation of
c-Kit, Gab1, Akt473, S6K, PLC, S6, and ERK, activated signalling pathways, and
then promoted cell proliferation and survival. shRNA-mediated silencing or genetic
knockout of Gai dramatically inhibited the phosphorylation of Akt473, Akt308,
GSK3a/3b, mTOR, S6K, S6, and ERK, which was activated by SCF.
Conclusion: The c-Kit-Gai complex transduces Akt-mTOR and Erk-MAPK down-
stream signalling activated by SCF, and then plays a key role in maintaining and
promoting the survival and proliferation of osteosarcoma cells. The target therapy
aimed at the complex will provide a new approach to curb and treat osteosarcoma.
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Introduction: Osteosarcoma (OS) is the most frequent primary bone sarcoma,
which is generally regarded as a differentiation disease that is caused by genetic
and epigenetic disruptions of terminal differentiation of osteoblasts. Bone
morphogenetic protein 9(BMP9) is probably the most osteogenic differentiation
potent inducer, but whether it can induce osteogenic differentiation of OS is un-
clear. All-trans retinoic acid (ATRA) can restore normal osteogenesis in OS. In
this study, we aim to identify the relationship between ATRA and BMP9 in inducing
osteogenesis differentiation of OS.
Subjects and Methods: 143B, OS cell line, were used to explore the mechanisms of
regulating differentiation and proliferation during treatment with ATRA and (or)
BMP9. The level of protein expression was tested by western blot assay. The levels
of mRNA expression were tested by Semi-quantitative RT-PCR (sqPCR). ALP activity
was assessed by a modified Great Escape SEAP Chemiluminescence assay. The pro-
liferation effects were tested by crystal violet staining.
Results: In 143B cells, BMP9 could not up-regulate the expression of osteogenesis
markers (such as Runx-2, Dlx-5, ALP, OPN, and OCN) but conversely, it could promote
proliferationof cells. Then,we found thatATRA successfully enhanced thesemarkers,
and it significantly inhibited proliferation of cells. The expression levels of BMP9were
up-regulated after ATRA treatment. Cells stimulated by treating with ATRA and BMP9
exhibited higher expression levels of osteogenesismarkers, than that treated byATRA
or BMP9, and also the effect of anti-proliferation of ATRA was enhanced. During dif-
ferentiation induction, the expression level of P-p38 was up-regulated with ATRA
treatment, which was higher than that with ATRA or BMP9 treatment. The osteogen-
esis markers induced by ATRA or ATRA and BMP9, were down-regulated by treated
with SB (p38 inhibitor SB203580). Meanwhile, SB could promote the proliferation of
143B cells; it also reversed the anti-proliferation of ATRA.
Discussion and Conclusion: According to the results of all above, we find that BMP9
fails to induce osteogenic differentiation of 143B cells alone, which is inconsistent
with the previous report that BMP2 can promote differentiation of OS, indicating
the existence of possible differentiation of BMP9 defects in OS. We found that ATRA
successfully induces osteoblastic differentiation of osteosarcoma cells in vitro and
it significantly inhibited proliferation of 143B cells, which is consistent with other re-
ports. Meanwhile, ATRA up-regulated the expression levels of BMP9 inOS. The expres-
sion levels of osteogenic-related genes were enhanced when BMP9 combined with
ATRA. Thus, we suppose that in the osteogenic potential restoration of BMP9 in OS,
ATRAmay play a critical role. During differentiation induction, the p38MAPK pathway
mayhavean important role in the control of osteogenesis-related genes expression. In
conclusion, this studydemonstrates thatATRAcanrestore theosteogeniccapabilityof
98 Session: Disease & TreatmentBMP9via activatep38MAPKpathway in osteosarcomacells,whichmayhelpus develop
efficacious differentiation therapies for osteosarcoma.
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Introduction: In this study, diclofenac (DCF) and kartogenin (KGN) were chosen as the
combined osteoarthritis (OA) cryotherapy to induce anti-inflammatory activity and
cartilage regeneration. Here, we designed a dual drug delivery system with thermo-
responsiveness for combined therapy of OA which is composed of pluronic F127
(F127)-chitosan oligosaccharide (COS)-KGN conjugated nanospheres (F127-COS-KGN
NPs) encapsulating DCF. The aims of this study were to: (1) characterize the F127/
COS/KGNDCF for controlleddual releaseby temperature changeandF127-COS-KGNDCF;
and (2) evaluate the combined therapeutic effects of the F127-COS-KGNDCF in vitro.
Subjects andMethods: (1) Preparation of F127-COS-KGNNPs loading DCF. The F127/
COS/KGNweremade by emulsification/solvent evaporationmethod. Conjugation of
F127-COOH and KGN with COS was carried out by EDC/NHS catalysis during the NPs
synthesis process. DCF was encapsulated inside the NPs by change of wall-perme-
ability according to temperature control. (2) Controlled dual release by temperature
change. The amounts of KGN and DCF released from the NPs were determined by
HPLC chromatography. (3) In vitro chondrogenic differentiation. The hBMSC
(2.5105 cells, passage 3-5) weremade by pellets. (4) In vitro anti-inflammatory ac-
tivity. After induction of inflammationwith lipopolysaccharide (LPS), the F127/COS/
KGNDCF was used to treat the cells. (5) In vivo thermo-responsiveness & retention
time in OA joint. OA was induced surgically using ACLT and DMM in rats. After IA in-
jection of the fluorescence dye-labelled F127/COS/KGNDCF, cold temperature (5C)
were applied around the joint for 10 minutes with a cryotherapy device. Fluores-
cence spectrum was scanned using an IVIS-spectrum measurement system. (6) In
vivo cyclooxygenase inhibition. Serum and synovium were collected in OA rats after
IA injection of the F127/COS/KGNDCF. COX-2 inhibition after cold temperature treat-
mentwas evaluated by RT-qPCR and ELISA. (7) In vivo cartilage regeneration. TheOA
rats were treated with F127/COS/KGNDCF by IA injection at weeks 6 and 9 after OA
induction. The distal femora in each group were dissected at 14 weeks after OA in-
duction and evaluated by Safranin-O staining and OARSI scoring. Immunohistochem-
istry of COL2 and ACAN was also carried out.
Results: (1) Preparation of F127-COS-KGN NCs loading DCF. The F127/COS/KGN are
-300 nm at 37C and expand to w650 nm when cooled to 4C. (2) In vitro release
study. While the encapsulated DCF showed burst release for 6 hours after cold
shock, the conjugated KGN showed sustained release for 14 days even though
the temperature changed. (3) In vitro chondrogenic differentiation. The gene
expression of COL2A1 and ACAN increased in hBMSCs pellets exposed to unconju-
gated KGN and both F127/COS/KGNDCF for 21 days compared with those of un-
treated hBMSCs. (4) In vitro anti-inflammatory activity. After cold shock
treatment, the F127/COS/KGNDCF treated chondrocytes showed rapid decrease
of IL-6 secretion. (5) In vivo thermo-responsiveness & retention time in OA joint.
The fluorescence signals from F127/COS/KGNDCF were observed in the knee joint
of OA rats up to 21 days. In particular, F127/COS/KGNDCF treated rats after cold
temperature treatment showed significantly higher fluorescence intensity than
those of rats untreated with cold temperature on days 2 (p < 0.01) and 5 (p <
0.05). (6) In vivo cyclooxygenase inhibition. After cold temperature treatment,
the F127/COS/KGNDCF injected rats showed decrease of COX-2 activity.
Discussion andConclusion: Both KGNandDCFwere released independently from the
F127/COS/KGNDCF by temperature control. COX-2 inhibitionbyDCF released from the
NCs after cold temperature treatment was confirmed. The F127/COS/KGNDCF can be
effectively combined therapeutic for OA by thermally controlled dual drug delivery.
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Background: At present, the population aging situation in China has become more
and more serious. Osteoporosis is one of the deadliest diseases that affect the
health of the elderly. Early detection and early prevention of osteoporosis can
help to avoid serious complications of osteoporosis, such as limb brittle fractures
or vertebral compression fractures. The extended life expectancy and increasing
number of elderly in the population means the arrival of an aging society. Quanti-
tative ultrasound (QUS) is a non-invasive method for evaluating bone mass density
developed in the 90s. It not only reflects the bone density, but also contributes toshow the bone strength and bone structure characteristics; therefore, it has the
value of diagnosing osteoporosis and predicting potential fracture risks as well.
At the same time it is convenient to carry and easy to operate. Asian osteoporosis
self-assessment tool (OSTA) is an easy and effective way to evaluate Asian people’s
osteoporosis. Neither OSTA nor QUS can solely achieve the desired sensitivity and
specificity when screening for osteoporosis, but it is a feasible way to combine
both methods. This study aims to explore the use of combining QUS and OSTA to
evaluate the risk of osteoporosis in a community of postmenopausal women.
Methods: From September 2014 to December 2014, bone mineral density of 118
postmenopausal women was measured in Guangzhou communities by quantitative
ultrasound measurement and relative information such as their ages and BMI were
collected through questionnaires. Patients also went through lumbar and dual-en-
ergy X-ray scans. DXA test results were taken as the gold standard of osteoporosis
diagnosis, by drawing an ROC curve, this research evaluates the feasibility of the
joined use of QUS and OSTA score in osteoporosis screening and determine the
appropriate diagnosis point.
Results: When combined use of OSTA and for screening, the regression curve was
fitted as YZ1.688*QUSe0.186*OSTAe3.973. Y was considered to be a predicted
value. Meanwhile, the AUC of ROC drawn by predicted value and DXA screening
result is 0.847, SEZ0.041.
Discussions and Conclusions: Quantitative Ultrasound (QUS) and OSTA score is a
simple and economic method of predicting the incidence of osteoporosis in the
elderly. By setting the QUS and OSTA threshold, it can effectively screen osteopo-
rosis in patients at high risk.
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Background: To investigate the optimum timing and how long to build the osteo-
porosis model in C57/BL6 mice by ovariectomy (OVX).
Methods: Fifty six-week-old female C57/BL6 mice were divided into ten groups (A-
J). Group A and F underwent BMDmeasurement by DEXA on cranium at eight-weeks-
old and twelve-weeks-old, respectively. The BMD analysis of group B-E was per-
formed at 8 weeks, 10 weeks, 12week, and 14 weeks after the mice underwent
OVX at eight weeks old. The BMD analysis of group G-J was performed at 6 weeks,
8 weeks, 10 week, and 12 weeks after themice underwent OVX at twelve weeks old.
Results: The mean BMD on the cranium of twelve-week-old mice (0.1310.030g/
cm2) was significantly higher than the BMD of eight-week-old mice
(0.1130.042g/cm2) (P<0.05). There was no significant difference between groups
A-E. The mean BMD on the cranium of group F (0.1310.030g/cm2) was signifi-
cantly higher than the BMD of group H (0.1130.014g/cm2) (P<0.05). The BMD
decreased smoothly from H-J (P>0.05).
Discussions and Conclusions: The optimum age to build up the osteoporosis model
in C57/BL6 mice is twelve weeks old and we should wait at least 8 weeks before
the model is established.
http://dx.doi.org/10.1016/j.jot.2016.06.195STIM1 REGULATED OSTEOBLAST DIFFERENTIATION IN THE DEVELOPMENT OF
POSTMENOPAUSAL OSTEOPOROSIS
Yuehu Han, Zhuojing Luo, Liu Yang
Xijing Hospital, the Fourth Military Medical University, China
Introduction: Calcium is required for a number of functions in the body. Past
research has established the strong correlation between calcium homeostasis
and supplementation leading to enhanced bone health in postmenopausal women.
However, calcium supplementation is not without controversy and benefits on skel-
etal health need to be balanced against potential risks. Results of recent clinical
trials indicate that calcium supplementation does not significantly reduce fracture
risk in postmenopausal woman. The underlying mechanisms of this controversy
have not been well defined. Stromal interaction molecule-1(STIM1) is localised in
the endoplasmic reticulum (ER), senses [Ca2+] ER, and activates the Ca
2+ release
activated Ca2+ (CRAC) channel upon store depletion. Recent research found that
CRAC channel plays an essential role in differentiation and function of osteoclasts
and osteoblasts. Here we have investigated the role of STIM1 in the osteogenic dif-
ferentiation of osteoblasts and postmenopausal osteoporosis.
Subjects and methods: BMMSCs were cultured in the presence of osteogenic in-
duction for 14 days after being obtained from postmenopausal osteoporosis pa-
tients. We analysed the Ca2+ concentration and CRAC channel by Fluo-3 staining
before and after osteogenic induction, respectively. STIM1 expression and osteo-
genic differentiation was further evaluated using quantitative real time PCR to
compare expression of STIM1 and osteogenic markers. We conducted knockdown
of one component of the CRAC channel, STIM1 in MC3T3-E1 using stable shRNA
interference. Detection of the osteogenic gene markers, ALP activity, and
